(MT Newswires) -- Novo Nordisk A/S (NVO) will sell its Wegovy obesity drug in larger European markets in 2023 after resolving production problems that has held back sales of the weekly injection in the US. Chief Executive Officer Lars Fruergaard Jorgensen speaks on "Bloomberg Markets."

Bloomberg videos